- Home
- INCR vs SRZN Comparison
INCR vs SRZN Comparison
Compare INCR & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- SRZN
- Stock Information
- Founded
- INCR 1994
- SRZN 2015
- Country
- INCR Israel
- SRZN United States
- Employees
- INCR N/A
- SRZN 41
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- INCR Health Care
- SRZN Health Care
- Exchange
- INCR Nasdaq
- SRZN Nasdaq
- Market Cap
- INCR 76.7M
- SRZN 65.5M
- IPO Year
- INCR N/A
- SRZN N/A
- Fundamental
- Price
- INCR $1.58
- SRZN $8.49
- Analyst Decision
- INCR
- SRZN Strong Buy
- Analyst Count
- INCR 0
- SRZN 2
- Target Price
- INCR N/A
- SRZN $38.50
- AVG Volume (30 Days)
- INCR 8.6K
- SRZN 13.0K
- Earning Date
- INCR 05-01-2025
- SRZN 05-09-2025
- Dividend Yield
- INCR N/A
- SRZN N/A
- EPS Growth
- INCR N/A
- SRZN N/A
- EPS
- INCR N/A
- SRZN N/A
- Revenue
- INCR $65,575,323.00
- SRZN $11,638,000.00
- Revenue This Year
- INCR $69.54
- SRZN N/A
- Revenue Next Year
- INCR $41.75
- SRZN N/A
- P/E Ratio
- INCR N/A
- SRZN N/A
- Revenue Growth
- INCR N/A
- SRZN N/A
- 52 Week Low
- INCR $1.17
- SRZN $5.90
- 52 Week High
- INCR $3.28
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- INCR 55.03
- SRZN 49.02
- Support Level
- INCR $1.51
- SRZN $5.90
- Resistance Level
- INCR $1.59
- SRZN $8.52
- Average True Range (ATR)
- INCR 0.05
- SRZN 0.79
- MACD
- INCR -0.00
- SRZN 0.15
- Stochastic Oscillator
- INCR 55.63
- SRZN 82.75
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).